Cantor Fitzgerald Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $85
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Olivia Brayer has maintained an Overweight rating on Bristol-Myers Squibb (NYSE:BMY) but lowered the price target from $88 to $85.
July 20, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol-Myers Squibb's price target has been lowered from $88 to $85 by Cantor Fitzgerald, though the Overweight rating is maintained.
The lowering of the price target by Cantor Fitzgerald could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Overweight rating indicates that the analyst still sees the stock as a good investment, which could counterbalance the negative impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100